The optimal dose and frequency of transplantation of the current DIABECELL preparation for the treatment of type 1 diabetes in humans can only be determined in clinical trials. The intention of this phase IIb clinical trial is to obtain at least 52 weeks safety and preliminary efficacy data in type 1 diabetic patients following transplantation of two effective doses of DIABECELL into the peritoneal cavity.